| pubmed-article:11722408 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0004623 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0008809 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0009316 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C1456627 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:11722408 | lifeskim:mentions | umls-concept:C1708528 | lld:lifeskim |
| pubmed-article:11722408 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11722408 | pubmed:dateCreated | 2001-11-27 | lld:pubmed |
| pubmed-article:11722408 | pubmed:abstractText | Following a 2-year study, the combination of oral ciprofloxacin and colistin has been used continuously for 10 years without the emergence of resistance. During a 2-year period (1987-1989), we compared ciprofloxacin + colistin (CIP + COL) with neomycin + colistin (NEO + COL) in a randomized trial--combinations chosen because of the potential for prophylaxis of Gram-negative infection by ciprofloxacin, with colistin given to reduce the risk of emergence of resistance. Sixty-four patients with similar demographics in each arm were evaluable for efficacy analysis. Patients on CIP + COL had a significantly lower proportion of neutropenic days with fever (P < 0.001) and neutropenic days on intravenous antibiotics (P < 0.001) than patients on NEO + COL. A total of 54 (15 bacteriologically documented) pyrexial episodes occurred in patients on CIP + COL and 77 (41 bacteriologically documented) in patients on NEO + COL. Only two Gram-negative bacterial infections occurred in the CIP + COL arm compared with 16 in the NEO + COL arm. No Staphylococcus aureus infections occurred in the CIP + COL group compared with 10 in the other patients. Two CIP-resistant Gram-negative bacilli were isolated from patients on CIP + COL compared with 13 NEO-resistant Gram-negative bacilli from patients on NEO + COL. Following a subsequent decade of unchanged use of this prophylactic strategy in neutropenic patients, a 2-year follow-up study between 1 January 1998 and 31 December 1999 showed 66 significant infections during 700 [corrected] neutropenic episodes. Thirty-five of the 111 (31%) isolates were ciprofloxacin-resistant, involving 5% of the neutropenic episodes [corrected]. | lld:pubmed |
| pubmed-article:11722408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11722408 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11722408 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11722408 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11722408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11722408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11722408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11722408 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11722408 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:11722408 | pubmed:issn | 0007-1048 | lld:pubmed |
| pubmed-article:11722408 | pubmed:author | pubmed-author:HannI MIM | lld:pubmed |
| pubmed-article:11722408 | pubmed:author | pubmed-author:PrenticeH GHG | lld:pubmed |
| pubmed-article:11722408 | pubmed:author | pubmed-author:PatersonPP | lld:pubmed |
| pubmed-article:11722408 | pubmed:author | pubmed-author:KibblerC CCC | lld:pubmed |
| pubmed-article:11722408 | pubmed:author | pubmed-author:NazarethBB | lld:pubmed |
| pubmed-article:11722408 | pubmed:author | pubmed-author:BhamraAA | lld:pubmed |
| pubmed-article:11722408 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11722408 | pubmed:volume | 115 | lld:pubmed |
| pubmed-article:11722408 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11722408 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11722408 | pubmed:pagination | 46-52 | lld:pubmed |
| pubmed-article:11722408 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:meshHeading | pubmed-meshheading:11722408... | lld:pubmed |
| pubmed-article:11722408 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11722408 | pubmed:articleTitle | Oral ciprofloxacin plus colistin: prophylaxis against bacterial infection in neutropenic patients. A strategy for the prevention of emergence of antimicrobial resistance. | lld:pubmed |
| pubmed-article:11722408 | pubmed:affiliation | Department of Haematology, Royal Free Hospital and The Royal Free & University College Medical School, Royal Free Campus, London, UK. g.prentice@rfc.ucl.ac.uk | lld:pubmed |
| pubmed-article:11722408 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11722408 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11722408 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11722408 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11722408 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11722408 | lld:pubmed |
